Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack "PERFORM"


Phase N/A Results N/A

Trial Description

To demonstrate the superiority of terutroban over a marketed drug (antithrombotic agent) in reducing the number of cerebrovascular and cardiovascular events in patients with cerebrovascular diseases.


  • Warfarin (Coumadin┬«)Drug
    Other Names: Coumadin
    Intervention Desc: Anticoagulant (Vitamin K antagonist)
  • S 18886 (Terutroban)Drug
    Intervention Desc: thromboxane receptor antagonist

Trial Design

Randomized, double-blind, parallel-group study

Patient Involvement

Patients 55 and greater post-stroke will be randomized to either S 18886 or an antithrombotic agent.


Type Measure Time Frame Safety Issue
Primary Cerebrovascular and cardiovascular events
Secondary Safety criteria


Institut de Recherches Internationales Servier (France)